Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions

REFERENCES

1. 1.↵
   1. Romero Pérez A,
   2. Queiro R,
   3. Seoane-Mato D, et al.

   Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLOS One 2020;15:e0234556.

   OpenUrl
2. 2.↵
   1. Coates LC,
   2. Soriano ER,
   3. Corp N, et al.

   Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465-79.

   OpenUrlPubMed
3. 3.↵
   1. Gossec L,
   2. Baraliakos X,
   3. Kerschbaumer A, et al.

   EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Mease P,
   2. Hall S,
   3. FitzGerald O, et al.

   Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017; 377:1537-50.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Gladman D,
   2. Rigby W,
   3. Azevedo VF, et al.

   Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525-36.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Galíndez-Agirregoikoa E,
   2. Prieto-Peña D,
   3. Martín-Varillas JL, et al.

   Treatment with tofacitinib in refractory psoriatic arthritis: a national multicenter study of the first 87 patients in clinical practice. J Rheumatol 2021;48:1552-8.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Lubrano E,
   2. Scriffignano S,
   3. Perrotta FM.

   Sequencing of biologic and target synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A perspective. Rheumatol Ther 2023;10:301-6.

   OpenUrl
8. 8.↵
   1. Queiro R,
   2. Loredo M,
   3. Braña I,
   4. Pardo E,
   5. Alonso S,
   6. Alperi M.

   Managing psoriatic arthritis in different clinical scenarios. Expert Rev Clin Immunol 2023;19:1469-84.

   OpenUrl
9. 9.↵
   1. Ballegaard C,
   2. Højgaard P,
   3. Dreyer L, et al.

   Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res 2018;70:592-9.

   OpenUrlPubMed
10. 10.↵
    1. Iannone F,
    2. Lopriore S,
    3. Bucci R, et al.

    Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings. J Rheumatol 2016;43:911-7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Alonso S,
    2. Villa I,
    3. Fernández S, et al.

    Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: secukinumab in Cantabria and ASTURias study. Front Med 2021;8:679009.

    OpenUrl
12. 12.↵
    1. Braña I,
    2. Pardo E,
    3. Burger S,
    4. González Del Pozo P,
    5. Alperi M,
    6. Queiro R.

    Treatment retention and safety of ixekizumab in psoriatic arthritis: a real life single-center experience. J Clin Med 2023;12:467.

    OpenUrl
13. 13.↵
    1. Pombo-Suárez M,
    2. Seoane-Mato D,
    3. Díaz-González F, et al.

    Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskelet Care 2023;21:189-97.

    OpenUrl
14. 14.
    1. Joven B,
    2. Hernández Sánchez R,
    3. Pérez-Pampín E, et al.

    Persistence and use of ixekizumab in patients with psoriatic arthritis in real-world practice in Spain. The PRO-STIP study. Rheumatol Ther 2023;10:1319-33.

    OpenUrl
15. 15.
    1. Joven B,
    2. Manteca CF,
    3. Rubio E, et al.

    Real-world persistence and treatment patterns in patients with psoriatic arthritis treated with anti-IL17 therapy in Spain: the PerfIL-17 study. Adv Ther 2023;40:5415-31.

    OpenUrl
16. 16.↵
    1. Glintborg B,
    2. Di Giuseppe D,
    3. Wallman JK, et al.

    Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis 2023; 82:820-8.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Egeberg A,
    2. Rosenø NAL,
    3. Aagaard D, et al.

    Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 2022;53:151979.

    OpenUrl
18. 18.↵
    1. Mease PJ,
    2. Orbai AM,
    3. FitzGerald O, et al.

    Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies. Arthritis Res Ther 2023;25:153.

    OpenUrl